Redx Pharma Plc's (LON:REDX) chief scientific officer Richard Armer sat down with Proactive London's Andrew Scott to discuss the opportunities ahead for their cancer and fibrosis portfolios.
Redx is ready to begin first-in-man trials of lead oncology drug, RXC004, in the first half of next year.
Putative fibrosis treatment RXC006 is expected to enter the clinic the year after.
Price: 8.25 GBX
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Redx Pharma Plc named herein, including the promotion by the Company of Redx Pharma Plc in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE
Redx Pharma PLC's (LON:REDX) chief scientific officer Dr Richard Armer speaks to Proactive London's Andrew Scott after announcing they'd won grant funding for their latest project. They're collaborating with the Medicines Discovery Catapult, a government body that helps accelerate the...
Retail & consumer
Mining
